Cardiovascular

Featured Article
Talking Therapeutics: Blood Pressure Potpourri
When combining the high prevalence of hypertension with new aggressive treatment targets, a lot of patients may face the risk of having to take numerous drugs. In this week’s issue of Talking Therapeutics, Dr Jennings looks at a few recent and interesting articles surrounding this timely topic.
Talking Therapeutics: Making Bloody Sense of Anticoagulation in Severe COVID-19 Infections
In this week’s issue of Talking Therapeutics, Dr Jennings examine the latest study surrounding the murky subject of anticoagulating patients with severe COVID-19 infection, and what it means for…
Talking Therapeutics: Fishing for Further Reductions in Residual Cardiovascular Risk
Dr Jennings reviews two of the latest trials evaluating the controversial topic of fish oils products, and attempts to get the bottom of this murky pond of conflicted evidence. 

Newsfeed

Talking Therapeutics: Blood Pressure Potpourri
Talking Therapeutics: Making Bloody Sense of Anticoagulation in Severe COVID-19 Infections
Talking Therapeutics: Fishing for Further Reductions in Residual Cardiovascular Risk
Antihypertensive Drug That Targets Genes May Increase Schizophrenia Risk
Study Review Highlights How Cardiovascular Disease Affects Women and Current Gaps in Care
Talking Therapeutics: Preserving Hope for Patients With HFpEF
How Do We Achieve Optimal Population Cardiovascular Health?
Update on Hypertension Epidemiology and Treatment for 2021
View More

Insights

Talking Therapeutics: Blood Pressure Potpourri
When combining the high prevalence of hypertension with new aggressive treatment targets, a lot of patients may face the risk of having to take numerous drugs. In this week’s issue of Talking Therapeutics, Dr Jennings looks at a few recent and…
Talking Therapeutics: Making Bloody Sense of Anticoagulation in Severe COVID-19 Infections
In this week’s issue of Talking Therapeutics, Dr Jennings examine the latest study surrounding the murky subject of anticoagulating patients with severe COVID-19 infection, and what it means for frontline pharmacists practicing in the hospital…
Talking Therapeutics: Fishing for Further Reductions in Residual Cardiovascular Risk
Dr Jennings reviews two of the latest trials evaluating the controversial topic of fish oils products, and attempts to get the bottom of this murky pond of conflicted evidence. 
Antihypertensive Drug That Targets Genes May Increase Schizophrenia Risk
Mark Munger, PharmD, explains why careful observation of patients being treated with ACEi based on salt classification may be warranted in patients with active symptoms or with a family history of schizophrenia.
View More

Interactive Features

CV Deaths, Hospitalizations Reduced for Patients Treated With Farxiga
In this episode of PopHealth Perspectives, Kiersten Combs, vice president, US Cardiovascular and Metabolic Disease (US CVMD) and Naeem Khan, MD, vice president, medical, US CVMD, AstraZeneca, discuss the recent approval of Farxiga (dapagliflozin),…
Reducing Major Bleeding, CVD-Associated Deaths With Edoxaban
Robert Giugliano, MD, cardiovascular medicine specialist at Brigham and Women's Hospital, discusses the results of the ENGAGE AF-TIMI 48 trial explaining the benefits of treating patients with edoxaban, and why he encourages health care…
Mortality Rates Lowered Among NH Residents Receiving Statins as Secondary Prevention
According to study findings, older adults receiving statins after acute myocardial infarction experienced reduced 1-year mortality by what percent?
Adherence Rates Among Patients With AF Who Began Anticoagulation Therapy
Among those who receive oral anticoagulation therapy, researchers were curious about the following question: “What are the longitudinal patterns of adherence to treatment with warfarin and direct oral anticoagulants among patients with atrial…
View More
Back to Top